Latest Headlines

Latest Headlines

With more consolidation on tap in generics, who's next to buy and be bought?

Teva's $40.5 billion deal for Allergan's generics business, announced last week, was just the latest to hit a rapidly consolidating generics industry. And while the M&A bug is sweeping through the wider pharma industry, in generics, there's an added factor pushing copycats to join hands.

Allergan braces for $200M sales hit as Namenda generics roll

Earlier this year, Allergan saw its plans to ease the pain from Namenda generics spoiled by a U.S. appeals court. And now, those generics are here.

Bad news for AstraZeneca: FDA lays out roadmap for would-be Symbicort copycats

The FDA has issued AstraZeneca's least favorite form of draft guidance--the kind that helps other drugmakers develop copies of a blockbuster seller.

Unions accuse Novartis of 'sham' patent fight to delay Sun's Gleevec generics

Two union funds are suing Novartis, claiming that the Swiss drugmaker used "sham" patent-infringement claims to delay a generic version of its blockbuster leukemia drug Gleevec. Though just the latest in a series of legal battles over drug patent settlements, it's the first attempt by purchasers to block one of those settlements, the plaintiffs' lawyers said.

Eli Lilly scores a multibillion-dollar win in Alimta's EU patent fight

Eli Lilly scored a victory in its patent battle for lung cancer blockbuster Alimta in Europe, as the Court of Appeal in London ruled against Actavis' plan to market copycat versions of the med.

Loaded up with debt from M&A binge, Valeant still needs more deals

Things appear to be going pretty smoothly for serial dealmaker Valeant since its failed bid for Allergan in November. The Canadian pharma bounced back with two deals earlier this year and is rumored to have another one in the works, helping it deliver on its goal of expanding into high-growth markets to become one of the world's top 5 drugmakers by 2016. But Valeant's M&A binge could be taking its toll on the company, even as it continues to ink new deals and score points with investors. 

UPDATED: U.S. court nixes Teva's Copaxone patent--again

It's been a long legal road for Copaxone, and one that took yet another turn Thursday as the U.S. Court of Appeals struck down the drug's patent for the second time.

Sun Pharma dispatches 18 top Ranbaxy execs in post-merger shift

After snapping up the troubled Indian generics maker Ranbaxy Laboratories in an all-stock deal last year, Sun Pharma has sent 18 top executives at its former rival packing, including Ranbaxy President and CFO Indrajit Banerjee and VP of marketing Maninder Singh, sources told The Economic Times.

Bad news for AbbVie: Humira copies expected to rack up biggest biosim sales

Here's something AbbVie doesn't want to hear: Industry watchers expect biosimilars for its top moneymaker Humira to be the most successful copycat biologics launched in the U.S. and Europe.

Does brand + generic really add up? Sandoz, Actavis execs count the ways

These days, companies are increasingly looking to put both branded and generic meds under one roof. And Peter Goldschmidt, the U.S. president of Novartis' Sandoz unit, doesn't know why they didn't do it sooner.